Analyst Ratings For Checkpoint Therapeutics Inc (NASDAQ:CKPT)
Today, HC Wainwright set its price target on Checkpoint Therapeutics Inc (NASDAQ:CKPT) to $11.00 per share.
There are 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Checkpoint Therapeutics Inc (NASDAQ:CKPT) is Buy with a consensus target price of $11.00 per share, a potential 178.48% upside.
Some recent analyst ratings include
- 3/22/2017-Checkpoint Therapeutics Inc (NASDAQ:CKPT) has coverage initiated with a Buy rating
About Checkpoint Therapeutics Inc (NASDAQ:CKPT)
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC. Its pipeline consists of glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. The company is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein, and poly polymerase. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Recent Trading Activity for Checkpoint Therapeutics Inc (NASDAQ:CKPT)
Shares of Checkpoint Therapeutics Inc closed the previous trading session at 3,89 −0,60 13,31 % with shares trading hands.
